Percutaneous Coronary Intervention and the Various Coronary Artery Disease Syndromes
暂无分享,去创建一个
[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[2] D. Lamm,et al. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer , 2015, Nature Reviews Urology.
[3] L. Fleisher,et al. Writing Committee Members 3 , 2014 .
[4] Jeroen J. Bax,et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.
[5] Eric Vicaut,et al. Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial , 2013 .
[6] David X M Zhao,et al. Comparison of 30-day outcomes of coronary artery bypass grafting surgery verus hybrid coronary revascularization stratified by SYNTAX and euroSCORE. , 2013, The Journal of thoracic and cardiovascular surgery.
[7] Tom Adriaenssens,et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.
[8] Antonio Colombo,et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.
[9] H. Swanton,et al. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[10] Lynn A. Sleeper,et al. Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial , 2013, Circulation.
[11] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[12] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[13] Harlan M Krumholz,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[14] D. Holmes,et al. Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.
[15] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.
[16] PubMed Id. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013 .
[17] Nancy M Albert,et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[18] Wei Wang,et al. Unrestricted utilization of frequency domain optical coherence tomography in coronary interventions , 2013, The International Journal of Cardiovascular Imaging.
[19] Akshay S. Desai,et al. Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.
[20] Sankey V. Williams,et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.
[21] M. Ergelen,et al. High SYNTAX score predicts worse in-hospital clinical outcomes in patients undergoing primary angioplasty for acute myocardial infarction , 2012, Coronary artery disease.
[22] E. Steyerberg,et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. , 2012, European heart journal.
[23] Giuseppe Biondi-Zoccai,et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[24] J. Cohn. Fractional flow reserve–guided PCI reduced urgent revascularization at 7 months in coronary artery disease , 2012, Annals of Internal Medicine.
[25] J. Messenger,et al. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. , 2012, Journal of the American College of Cardiology.
[26] Inder Singh,et al. Percutaneous left ventricular assist device with TandemHeart for high‐risk percutaneous coronary intervention: The Mayo Clinic experience , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[27] P. Serruys,et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.
[28] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[29] Y. Jang,et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.
[30] J. Marsal,et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. , 2012, Journal of the American College of Cardiology.
[31] D. Holmes,et al. Percutaneous Coronary Intervention at Centers With and Without On-site Surgery , 2012 .
[32] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[33] Nikola Jagic,et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. , 2012, The New England journal of medicine.
[34] Y. Hayashi,et al. Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.
[35] P. Serruys,et al. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[36] Jean-Claude Tardif,et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry , 2012, European heart journal.
[37] L. Räber,et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. , 2012, JAMA.
[38] A. Kirtane,et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.
[39] D. Berman,et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. , 2012, American heart journal.
[40] Takashi Akasaka,et al. Application of optical coherence tomography in percutaneous coronary intervention. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[41] P. Serruys,et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. , 2012, Journal of the American College of Cardiology.
[42] Deepak L. Bhatt,et al. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[43] S. Windecker,et al. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? , 2012, Circulation. Cardiovascular interventions.
[44] E. Steyerberg,et al. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. , 2012, JACC: Cardiovascular Interventions.
[45] M. Mack,et al. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. , 2012, JACC. Cardiovascular interventions.
[46] P. Serruys,et al. Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials , 2012, Circulation. Cardiovascular interventions.
[47] D. Faxon,et al. Prolonged Clopidogrel Use After Bare Metal and Drug-Eluting Stent Placement: The Veterans Administration Drug-Eluting Stent Study , 2012, Circulation. Cardiovascular interventions.
[48] Manesh R. Patel,et al. Hospital Percutaneous Coronary Intervention Appropriateness and In-Hospital Procedural Outcomes: Insights From the NCDR , 2012, Circulation. Cardiovascular quality and outcomes.
[49] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[50] Sean M. O'Brien,et al. Comparative effectiveness of revascularization strategies. , 2012, The New England journal of medicine.
[51] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.
[52] J. Rodés‐Cabau,et al. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art , 2012, Annals of the New York Academy of Sciences.
[53] D. Berman,et al. Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial). , 2012, The American journal of cardiology.
[54] Marco Valgimigli,et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.
[55] J. Marchesini,et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.
[56] C. Terkelsen,et al. Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.
[57] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[58] Duane Pinto,et al. Economic outcomes of percutaneous coronary intervention with drug‐eluting stents versus bypass surgery for patients with left main or three‐vessel coronary artery disease: One‐year results from the SYNTAX trial , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[59] B. Gersh,et al. Procedural factors associated with percutaneous coronary intervention-related ischemic stroke. , 2012, JACC. Cardiovascular interventions.
[60] C. Conti,et al. Silent ischemia: clinical relevance. , 2012, Journal of the American College of Cardiology.
[61] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[62] E. Braunwald,et al. A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.
[63] Subhash Banerjee,et al. The retrograde approach to coronary artery chronic total occlusions , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[64] Hani Jneid,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.
[65] D. Holmes,et al. Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. , 2011, JAMA.
[66] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[67] Jeffrey L. Anderson,et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.
[68] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.
[69] F. Eberli,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.
[70] D. Berman,et al. Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy: Observations From the COURAGE Trial , 2011, Circulation. Cardiovascular interventions.
[71] U. Siebert,et al. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. , 2011, JACC. Cardiovascular interventions.
[72] Inder Singh,et al. Myocardial revascularization by percutaneous coronary intervention: past, present, and the future. , 2011, Current problems in cardiology.
[73] M. Leon,et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. , 2011, JACC. Cardiovascular interventions.
[74] Samin K. Sharma,et al. Impact of Incomplete Revascularization on Long-Term Mortality After Coronary Stenting , 2011, Circulation. Cardiovascular interventions.
[75] B. De Bruyne,et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. , 2011, Journal of the American College of Cardiology.
[76] G. Stone,et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. , 2011, JACC. Cardiovascular interventions.
[77] Harlan M Krumholz,et al. Improvements in Door-to-Balloon Time in the United States, 2005 to 2010 , 2011, Circulation.
[78] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[79] D. Holmes,et al. Clinical ResearchInterventional CardiologyCulprit Vessel Only Versus Multivessel and Staged Percutaneous Coronary Intervention for Multivessel Disease in Patients Presenting With ST-Segment Elevation Myocardial Infarction: A Pairwise and Network Meta-Analysis , 2011 .
[80] C. Di Mario,et al. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[81] E. Barbato,et al. From SYNTAX to FAME, a paradigm shift in revascularization strategies: the key role of fractional flow reserve in guiding myocardial revascularization. , 2011, Journal of cardiovascular medicine.
[82] Y. Iesaka,et al. Impact of Coronary Plaque Morphology Assessed by Optical Coherence Tomography on Cardiac Troponin Elevation in Patients With Elective Stent Implantation , 2011, Circulation. Cardiovascular interventions.
[83] Kevin Kennedy,et al. Appropriateness of percutaneous coronary intervention. , 2011, JAMA.
[84] D. Berman,et al. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. , 2011, Journal of the American College of Cardiology.
[85] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[86] G. Stone,et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. , 2011, Journal of the American College of Cardiology.
[87] J. Spertus,et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. , 2011, JAMA.
[88] Samin K. Sharma,et al. Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-ST-segment elevation myocardial infarction. , 2011, The American journal of cardiology.
[89] C. Danzer,et al. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rational , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[90] T. Ryan,et al. Recent Changes in Practice of Elective Percutaneous Coronary Intervention for Stable Angina , 2011, Circulation. Cardiovascular quality and outcomes.
[91] Charles Maynard,et al. Trends in Coronary Revascularization in the United States From 2001 to 2009: Recent Declines in Percutaneous Coronary Intervention Volumes , 2011, Circulation. Cardiovascular quality and outcomes.
[92] D. Berman,et al. The Cost-Effectiveness of Percutaneous Coronary Intervention as a Function of Angina Severity in Patients With Stable Angina , 2011, Circulation. Cardiovascular quality and outcomes.
[93] J. Herrmann,et al. Myocardial infarction due to percutaneous coronary intervention. , 2011, The New England journal of medicine.
[94] R. O'rourke,et al. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use? , 2011, Current treatment options in cardiovascular medicine.
[95] Pascal Vranckx,et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. , 2011, Journal of the American College of Cardiology.
[96] P. Serruys,et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.
[97] Uwe Siebert,et al. Economic Evaluation of Fractional Flow Reserve–Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease , 2010, Circulation.
[98] F. Eberli,et al. Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.
[99] M. Pencina,et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent , 2010, American heart journal.
[100] H. Gurm,et al. Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. , 2010, Archives of internal medicine.
[101] M. Jeong,et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. , 2010, Journal of the American College of Cardiology.
[102] J. Moses,et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. , 2010, JACC. Cardiovascular interventions.
[103] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[104] G. Stone,et al. Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HOR , 2010, Circulation.
[105] William Wijns,et al. Experience with revascularization procedures does matter: low volume means worse outcome. , 2010, European heart journal.
[106] Uwe Siebert,et al. Clinical ResearchInterventional CardiologyFractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study , 2010 .
[107] M. Jeong,et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgi , 2010, Journal of the American College of Cardiology.
[108] P. Armstrong,et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. , 2010, European heart journal.
[109] K. Oldroyd,et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. , 2010, Journal of the American College of Cardiology.
[110] M. Mack,et al. Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial , 2010, Circulation.
[111] S. Pocock,et al. A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.
[112] V. Fuster,et al. General Cardiology Perspective: Decision Making Regarding Revascularization of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial , 2010, Circulation.
[113] Seung‐Jung Park,et al. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score for prediction of outcomes after unprotected left main coronary revascularization. , 2010, JACC: Cardiovascular Interventions.
[114] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[115] C. Macaya,et al. Is refined OCT guidance of stent implantation needed? , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[116] D. Faxon,et al. Coronary Intervention in Patients With Acute Coronary Syndrome: Does Every Culprit Lesion Require Revascularization? , 2010, Current cardiology reports.
[117] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[118] C. Sosnowski. [Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus- -eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 2010; 375: 201-209]. , 2010, Kardiologia polska.
[119] G. Campo,et al. Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[120] R. Neumar,et al. Regional systems of care for out-of-hospital cardiac arrest: A policy statement from the American Heart Association. , 2010, Circulation.
[121] G. Angelini,et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. , 2010, Journal of the American College of Cardiology.
[122] Y. Hayashi,et al. In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). , 2010, JACC. Cardiovascular interventions.
[123] Habib Samady,et al. Current concepts of integrated coronary physiology in the catheterization laboratory. , 2010, Journal of the American College of Cardiology.
[124] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[125] Samin K. Sharma,et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. , 2010, JACC. Cardiovascular interventions.
[126] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[127] J. Ornato,et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[128] E. Hannan,et al. Outcomes for Patients With ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York State Experience , 2009, Circulation. Cardiovascular interventions.
[129] A. Kastrati,et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. , 2009, European heart journal.
[130] C. Gibson,et al. Outcomes Among Patients With ST-Segment–Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery , 2009, Circulation. Cardiovascular quality and outcomes.
[131] C. Gibson,et al. Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. , 2009, JACC. Cardiovascular interventions.
[132] J. Spertus,et al. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. , 2009, Archives of internal medicine.
[133] R. Weiss,et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. , 2009, JACC. Cardiovascular interventions.
[134] J. Rumsfeld,et al. Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR). , 2009, Journal of the American College of Cardiology.
[135] M. Jeong,et al. Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2009, Circulation.
[136] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[137] S. Pocock,et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials , 2009, The Lancet.
[138] Yi Li,et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. , 2009, American heart journal.
[139] K. Filion,et al. Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents , 2009, Circulation.
[140] Y. Hayashi,et al. Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.
[141] Mario J. Garcia,et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[142] Frederick A. Masoudi,et al. ACCF/SCAI/STS/MTS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Commentary , 2009 .
[143] Seung‐Jung Park,et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. , 2008, JACC. Cardiovascular interventions.
[144] Aloke V. Finn,et al. Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.
[145] A. Jaffe,et al. Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary InterventionCLINICAL PERSPECTIVE , 2008 .
[146] David R. Holmes,et al. Catheter-Based Treatment of Coronary Artery Disease: Past, Present, and Future , 2008, Circulation. Cardiovascular interventions.
[147] A. Jaffe,et al. Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention: An Analysis of Preintervention and Postintervention Troponin T Levels in 5487 Patients , 2008, Circulation. Cardiovascular interventions.
[148] D. Atar,et al. Bleeding risks of combination vs. single antiplatelet therapy: a meta‐analysis of 18 randomized trials comprising 129 314 patients , 2008, Fundamental & clinical pharmacology.
[149] J. Trickett,et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. , 2008, The New England journal of medicine.
[150] Deepak L. Bhatt,et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. , 2008, American heart journal.
[151] C. W. Barth,et al. Outcomes of 1,090 consecutive, elective, nonselected percutaneous coronary interventions at a community hospital without onsite cardiac surgery. , 2008, The American journal of cardiology.
[152] E. Antman,et al. Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.
[153] John Bresnahan,et al. Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.
[154] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[155] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[156] Timothy D. Henry,et al. A Regional System to Provide Timely Access to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction , 2007, Circulation.
[157] B. Gersh,et al. Twenty-Five–Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary Intervention: A Single-Institution Experience , 2007, Circulation.
[158] Antonio Colombo,et al. Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation , 2007, Circulation.
[159] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[160] H. Wiste,et al. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. , 2007, Journal of the American College of Cardiology.
[161] D. Berman,et al. Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.
[162] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[163] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[164] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[165] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[166] K. Kent,et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries. , 2007, The American journal of cardiology.
[167] Deepak L. Bhatt,et al. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? , 2007, Journal of the American College of Cardiology.
[168] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[169] C. Grines,et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.
[170] C. Grines,et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[171] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[172] P. Vardas,et al. Guidelines on the management of stable angina pectoris. , 2006, European heart journal.
[173] Deepak L. Bhatt,et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. , 2006, Journal of the American College of Cardiology.
[174] G. Montalescot,et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.
[175] A. Kastrati,et al. Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.
[176] E. Antman,et al. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial , 2005, Circulation.
[177] W. Herzog,et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.
[178] M. A. Kellett,et al. Outcomes of Percutaneous Coronary Interventions Performed at Centers Without and With Onsite Coronary Artery Bypass Graft Surgery , 2004 .
[179] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[180] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[181] M. Grzybowski,et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. , 2003, JAMA.
[182] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .
[183] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[184] M. Bell,et al. Correlates of procedural complicationsand a simple integer risk scorefor percutaneous coronary intervention , 2002 .
[185] W. O’Neill,et al. Multiple complex coronary plaques in patients with acute myocardial infarction. , 2000, The New England journal of medicine.
[186] M. Bertrand,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.
[187] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[188] C. Macaya,et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.
[189] E. Fleck,et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.
[190] T. B. Investigators,et al. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.
[191] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[192] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[193] M. Hadamitzky,et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.
[194] R E Vlietstra,et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1988, Journal of the American College of Cardiology.
[195] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[196] T. Ryan,et al. Follow-up of patients from the coronary artery surgery study (CASS) potentially suitable for percutaneous transluminal coronary angioplasty. , 1983, American heart journal.
[197] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.